Currently, a few synthetic LIPG inhibitors have been reported with inhibition efficiency in cell-free LIPG enzyme assays [55,56]; however, these inhibitors cannot be used to treat breast cancer due to poor permeability in tumor cells. Here, LIPG is linked to breast cancer.